TITLE:
The Effect of Luteal-Phase Support with Triptrolin Administration on Implantation and Clinical Pregnancy Rate in Assisted Reproductive Technology
AUTHORS:
Marzieh Aghahosseini, Ashraf Alleyassin, Leili Safdarian, Saeedeh Gharahjeh, Hojat Saeidi, Fatemeh Sarvi, Sedigheh Hosseini, Nooshin Mohammadi, Golamreza Roshandel, Jalal Gharajeh
KEYWORDS:
Luteal Phase Support, GnRH Agonist, Implantation Rate, Clinical Pregnancy
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.7 No.5,
May
26,
2017
ABSTRACT: Background: Luteal phase support with GnRH agonist administration has been shown to be effective in improving the outcome of assisted reproductive technology. The goal of this study was to evaluate the effect of single dose Triptrolin (a GnRH agonist) on the probability of the clinical pregnancy rate following embryo transfer (ET) in assisted reproductive techniques (ART). Methods: In this double blinded randomized clinical trial, 340 infertile women who were candidates for intra-cytoplasmic sperm injection (ICSI) were randomly assigned to receive GnRH agonist (Triptrolin) in the luteal phase or placebo. In the intervention group, 0.1 mg Triptrolin was injected subcutaneously, while the control group received normal saline. The clinical pregnancy and implantation rate were compared between the two groups using chi-2 and t-test. P-values less than 0.05 were considered significant. The registration number of this clinical trial is IRCT 2014030916912N1. Results: Administration of 0.1 mg Triptrolin on day 6 after oocyte pick up showed no superiority over placebo in implantation (16.9% - 14%, P = 0.40) and clinical pregnancy rates (32% - 29%, P = 0.66), but the rate of clinical pregnancy was higher in women who were below 27 years of age and those with PCO. Conclusion: Administration of Triptrolin was not superior to placebo for luteal phase support.